Barclays’s Foundation Medicine, Inc. FMI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-19,628
Closed -$2.68M 7657
2018
Q2
$2.68M Buy
19,628
+14,709
+299% +$1.34M ﹤0.01% 2292
2018
Q1
$387K Buy
4,919
+1,197
+32% +$88.3K ﹤0.01% 4222
2017
Q4
$254K Buy
3,722
+2,057
+124% +$107K ﹤0.01% 4483
2017
Q3
$66K Buy
1,665
+1,655
+16,550% +$63.9K ﹤0.01% 5196
2017
Q2
$0 Sell
10
-421
-98% -$15.4K ﹤0.01% 7154
2017
Q1
$14K Sell
431
-1,268
-75% -$31.6K ﹤0.01% 5967
2016
Q4
$29K Sell
1,699
-859
-34% -$18.5K ﹤0.01% 5458
2016
Q3
$60K Sell
2,558
-16,867
-87% -$383K ﹤0.01% 4874
2016
Q2
$363K Sell
19,425
-18,078
-48% -$327K ﹤0.01% 3476
2016
Q1
$675K Buy
37,503
+37,038
+7,965% +$597K ﹤0.01% 2872
2015
Q4
$10K Sell
465
-8,699
-95% -$168K ﹤0.01% 5419
2015
Q3
$165K Sell
9,164
-15,184
-62% -$379K ﹤0.01% 4284
2015
Q2
$804K Buy
24,348
+22,934
+1,622% +$923K ﹤0.01% 3079
2015
Q1
$69K Buy
1,414
+80
+6% +$3.63K ﹤0.01% 5080
2014
Q4
$29K Buy
1,334
+853
+177% +$19.7K ﹤0.01% 6098
2014
Q3
$9K Buy
481
+192
+66% +$4.58K ﹤0.01% 6964
2014
Q2
$8K Sell
289
-44
-13% -$1.11K ﹤0.01% 6966
2014
Q1
$11K Sell
333
-2,450
-88% -$79.6K ﹤0.01% 6900
2013
Q4
$63K Buy
+2,783
New +$77.8K ﹤0.01% 6017

Barclays's FMI Position: Q3 2018 in Review

Barclays sold out of Foundation Medicine, Inc. (FMI) in Q3 2018, closing a stake of 19,628 shares — an estimated $2.68M sold.

Barclays first reported a position in FMI in Q4 2013 and held it in 19 quarters. The position peaked at $2.68M in Q2 2018. 0 funds tracked by Wall St. Rank hold FMI as of Q3 2018.

  • Barclays reported no remaining Foundation Medicine, Inc. position as of Q3 2018 after selling out during the quarter.
  • Barclays sold 19,628 Foundation Medicine, Inc. shares in Q3 2018, an estimated $2.68M.
  • Barclays first reported a position in Foundation Medicine, Inc. in Q4 2013 and held it in 19 quarters.
  • Barclays's Foundation Medicine, Inc. position peaked at $2.68M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Foundation Medicine, Inc. as of Q3 2018.

Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.